Company Overview
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Recent Developments
- Dec 2025 Revenue of $7.95M (+123.6% YoY); net profit $-21.23M.
- Trailing 12 Months Year-on-year growth — revenue +49.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 49.00% |
Stock Price Performance
| 1 Year: | -25.65% |
| 6 Months: | -4.75% |
| 3 Months: | +1.32% |
| 1 Month: | -4.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 37.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COYA Coya Therapeutics, Inc. PHARMA | 4.61 | -4.31 | $108.14M | 0.00% | -51.17% | -60.54% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 126.84K | 3.43M | 0 | 257.88K | 163.62K | 3.56M | 251.15K |
| Operating Income | -1.70M | -3.45M | -2.66M | -2.90M | -3.25M | -3.56M | -5.48M | -3.24M | -4.45M | -7.68M | -6.41M | -2.43M | -7.64M |
| Net Income | -1.70M | -3.41M | -4.02M | -2.74M | -3.10M | -3.42M | -5.05M | -2.89M | -4.02M | -7.31M | -6.09M | -2.12M | -7.21M |
| Diluted EPS | -0.66 | -1.32 | -1.55 | -0.28 | -0.31 | -0.34 | -0.35 | -0.19 | -0.26 | -0.44 | -0.36 | -0.13 | -0.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 6.00M | 3.55M | 7.95M |
| Operating Income | -4.87M | -9.81M | -7.90M | -17.25M | -22.56M |
| Net Income | -4.89M | -12.24M | -7.99M | -14.88M | -21.23M |
| Diluted EPS | -1.89 | -4.73 | -0.79 | -0.98 | -1.27 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 4.79M | 8.40M | 41.26M | 44.35M | 49.95M |
| Total Equity | 8.30M | 3.64M | -8.39M | 35.64M | 39.58M | 43.03M |
| Cash & Equivalents | - | 4.34M | 5.93M | 32.63M | 38.34M | 46.82M |
| Total Liabilities | - | 1.15M | 16.79M | 5.63M | 4.77M | 6.92M |
| Current Liabilities | - | 1.15M | 3.82M | 5.05M | 3.82M | 5.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.90M | -7.24M | -11.19M | -10.29M | -10.74M |
| Investing Cash Flow | -136.80K | -525.00K | -543.19K | -25.00K | -1.16M |
| Financing Cash Flow | -340.58K | 9.36M | 38.43M | 16.03M | 20.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | -131.7% | -485.4% | -283.9% |
| Net Margin % | - | - | -133.1% | -418.7% | -267.1% |
| ROE % | -134.3% | 145.9% | -22.4% | -37.6% | -49.3% |
| ROCE % | -133.7% | -214.6% | -21.8% | -42.6% | -51.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | DME Capital Management, LP | 9.96% | 2.34M | $11.42M |
| 2 | Vanguard Capital Management LLC | 3.59% | 842.22K | $4.12M |
| 3 | Alyeska Investment Group, L.p. | 3.41% | 800.00K | $3.91M |
| 4 | AIGH Capital Management LLC | 2.69% | 631.91K | $3.09M |
| 5 | CM Management, LLC | 1.71% | 400.00K | $1.96M |
| 6 | Private Management Group, Inc. | 1.64% | 384.22K | $1.88M |
| 7 | Marshall Wace LLP | 1.06% | 249.79K | $1.22M |
| 8 | Geode Capital Management, LLC | 0.97% | 228.24K | $1.12M |
| 9 | Renaissance Technologies, LLC | 0.82% | 192.99K | $943.70K |
| 10 | Prosight Management, Lp | 0.72% | 170.00K | $831.30K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COYA
An experimental two-drug treatment cut inflammation signals in mice. Coya’s COYA 303 also raised immune-regulating markers. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQeTlFT05xZ3RTQzJKRGRmSlotOWpiZVEzV2pTOUgzS1Z2aEx6ejgtbjktQ05mbmVRZFRDVTlRbURpMURaQkFZeG81VWtyYjVYTUJ5Q2k4Unp6eUFmNEd5VTNfU1dfV1N0b1JkM3IxLVk1MHlWQlRRcUdVWURQUVhJVDRkalp5cTZhRi1xeV…
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQM1RkWkh2WTB4UGE5YWgzT1NuZDNWN2Q4aDRQNEZJQ1A5MXhzdkRIRG5jcmRxT25ERGt2MnRsOWRHbklIRFlOd0hkRTB5Mi1ncG5GYUVZM2hTNXc2M0RkZWIyNkhFOHA1T0ljREdEMTc1Q3gwSC1VaElhNUlUWlVwUEJFclRQaUpLN242dk…
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million | COYA Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxONzlGX3FveWpDR2FsdnRUb0FpME5TVUNfN0hMTUJOU2pkMW40V0RvZVRRLWRYbTJDQzBGcGJUMEh2dnZmb0g2VEFaSllEaHZuVmZtOWdSN1dYU0NiSjY1dktuVHN0ZElWU1RfanV0WHZoaThPSHhvLXBvbnhBTml6VER2QWpyWlJsNWRhWX…
Here's Why We're Not Too Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOSVF4ZWNRRVcxeWk5cUo1aTRWNjFEMVdXUkpPQk9iSXNOOFV0czJ4U2c0ZDFkWmZOZURpMm51VXNjVTBEQWgxQW5nTkh5Ry1rOXhKY0lxZ1pKSWd3TTR4VUlRa2lTRnBZNkJsZ2xna091YTVZODhzQzIwTVA3QXdHNTN6ZFQzTVEyQnJvST…
COYA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBMWXpQTy1xLXlpWTBXRFVDY0F5SjZ5Sk5JRjh4UkpELTFpMGZaWVVuQjJrN2dqN1RDX2lOU2M3QlZaMnZzdWc?oc=5" target="_blank">COYA</a> <font color="#6f6f6f">Finviz</font>…
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPTGZRYUVva0Z2ZkR2UEEtMTdIWUNlNnVldUVXeWhuYnc2YVpYWXZDVGU1N3hLTFZYdmRDaVNfd3RlRlNtMDI5WnhUVXZWcXlWR2RIZUJkMDFvV1VnQjNLVzN4Z29vUDVkZkd6YjlZbTh4MWFRYWp6ZG9wUXlGTzVqemtGQkgzcV9FVFJJQ1…
COYA — Frequently Asked Questions
What is the current share price of Coya Therapeutics, Inc. (COYA)?
As of 2026-09-19 21:16 PDT, Coya Therapeutics, Inc. (COYA) trades at $4.61 on NasdaqCM. Its 52-week range is $3.78 to $7.36.
What is the market capitalisation of COYA?
Coya Therapeutics, Inc. (COYA) has a market capitalisation of $108.14M on NasdaqCM.
What is the P/E ratio of COYA?
COYA trades at a trailing price-to-earnings (P/E) ratio of -4.31. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.50.
What is the return on equity (ROE) of COYA?
COYA has a return on equity (ROE) of -60.54%. Its return on capital employed (ROCE) is -51.17%.
Is COYA a good stock to buy?
This page provides a data-driven analysis of Coya Therapeutics, Inc. (COYA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.